CSAC has executed agreements to acquire 5 existing companies to create an anchor portfolio (the “Anchor Portfolio”) of vertically integrated operations in the Eastern and Western United States, pending regulatory approval on licensing and structure… Continue reading “Cannabis Strategies Acquisition Corp. Announces Proposed Qualifying Transaction”
Strong fourth quarter sales growth sees KushCo Holdings expect to become first U.S. based publicly-traded company in the cannabis industry to generate over $51 million in revenue annually
GARDEN GROVE, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) — KushCo Holdings, Inc. (OTCQB: KSHB) (“KushCo” or the “Company”), the parent company of innovative cannabis industry leaders such as Kush Bottles, Kush Energy, The Hybrid Creative, and Koleto Packaging Solutions, which provide a range of services and products for the regulated cannabis, CBD and other related industries, announced today that the Company is expecting to report over $51 million in annual revenue for the fiscal year ended August 31st, 2018, representing an increase of approximately 171% compared with the fiscal year ended August 31st, 2017. Continue reading “KushCo Holdings, Inc. Reports Preliminary Fiscal Year 2018 Revenue of Approximately $51M”
Massachusetts hit another milestone in its era of legalized marijuana: State regulators granted Cultivate a license to sell recreational marijuana at the company’s existing medical marijuana dispensary in Leicester.
The five-member Cannabis Control Commission unanimously voted to grant the retail license to Cultivate Holdings, Inc., which operates the first medical marijuana dispensary in Worcester County. Continue reading “MMJ Dispensary In Massachusetts Receives First License To Sell Recreational Cannabis”
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded with the volume of 18.78 Million in the previous trading session. The Stock opened its session at $14.7 and closed at $13.99 by showing decrease of -5.02 percent. Valeant Pharmaceuticals International, Inc. has 1 year price target of $23.87. Continue reading “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Current Opinions and Recommendations”